PRRT2 and metabolic dysfunction-associated steatotic liver disease: Modulation of DAG levels as well as their altered fatty acid composition could greatly affect PKC and other pathways, and as such, the progression of NAFLD and perhaps the risk of malignancy in the setting of NAFLD.